Dermal substitutes in keloid surgery: A systematic review and analysis of 116 lesions.

IF 0.5 4区 医学 Q4 SURGERY
B Roche, G Châtelier, T Lanson, E Cannaferina, P Alessandri, E Caubet, V Pinsolle, A Michot, B Hoteit, A Delgove
{"title":"Dermal substitutes in keloid surgery: A systematic review and analysis of 116 lesions.","authors":"B Roche, G Châtelier, T Lanson, E Cannaferina, P Alessandri, E Caubet, V Pinsolle, A Michot, B Hoteit, A Delgove","doi":"10.1016/j.anplas.2026.03.003","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Keloids are pathological scars characterized by excessive fibroproliferation and high recurrence rates after surgical excision. Dermal substitutes have been proposed as an adjunct to keloid surgery because they restore a stable dermal matrix, reduce mechanical tension, and may modulate fibroblast activity. However, their clinical effectiveness in preventing recurrence remains insufficiently defined. This study aimed to systematically review the available literature on the use of dermal substitutes following keloid excision.</p><p><strong>Methods: </strong>A systematic review was conducted according to PRISMA guidelines. Medline, Embase, Web of Science were searched from inception to January, 2026. Eligible studies included clinical reports using a dermal substitute after complete keloid excision with at least 6 months of follow-up and explicit recurrence data. Case reports, case series, and conference abstracts with sufficient clinical detail were included. Extracted variables comprised patient characteristics, lesion features, substitute type, operative protocol, adjuvant therapy, follow-up, recurrence. Due to heterogeneity, a descriptive synthesis was performed.</p><p><strong>Results: </strong>Twenty studies were included, representing 109 patients and 116 keloid lesions. Most publications ware case series or case reports (Level IV-V evidence). Integra® was the most frequently used substitute, followed by Pelnac®, AlloDerm®, and Apligraf®. Reconstruction was most commonly performed using a two-stage approach with delayed split-thickness skin grafting. At 6 months, only one recurrence was reported among the studies providing early follow-up data. However, a recent larger retrospective cohort reported a recurrence rate of 28.8% after long-term follow-up. Adjuvant therapies such as radiotherapy, triamcinolone, and 5-fluorouracil were frequently combined with dermal substitute reconstruction.</p><p><strong>Conclusions: </strong>Dermal substitutes appear to be a promising adjunct in the surgical management of keloids, providing favorable aesthetic outcomes and low early recurrence rates. However, recurrence remains possible over long-term follow-up, and the independent effect of dermal matrices remains difficult to isolate due to frequent use of multimodal treatment protocols. Prospective studies with standardized surgical techniques and long-term follow-up are needed to better define the role of dermal substitutes in keloid surgery.</p>","PeriodicalId":55512,"journal":{"name":"Annales De Chirurgie Plastique Esthetique","volume":" ","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales De Chirurgie Plastique Esthetique","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.anplas.2026.03.003","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Keloids are pathological scars characterized by excessive fibroproliferation and high recurrence rates after surgical excision. Dermal substitutes have been proposed as an adjunct to keloid surgery because they restore a stable dermal matrix, reduce mechanical tension, and may modulate fibroblast activity. However, their clinical effectiveness in preventing recurrence remains insufficiently defined. This study aimed to systematically review the available literature on the use of dermal substitutes following keloid excision.

Methods: A systematic review was conducted according to PRISMA guidelines. Medline, Embase, Web of Science were searched from inception to January, 2026. Eligible studies included clinical reports using a dermal substitute after complete keloid excision with at least 6 months of follow-up and explicit recurrence data. Case reports, case series, and conference abstracts with sufficient clinical detail were included. Extracted variables comprised patient characteristics, lesion features, substitute type, operative protocol, adjuvant therapy, follow-up, recurrence. Due to heterogeneity, a descriptive synthesis was performed.

Results: Twenty studies were included, representing 109 patients and 116 keloid lesions. Most publications ware case series or case reports (Level IV-V evidence). Integra® was the most frequently used substitute, followed by Pelnac®, AlloDerm®, and Apligraf®. Reconstruction was most commonly performed using a two-stage approach with delayed split-thickness skin grafting. At 6 months, only one recurrence was reported among the studies providing early follow-up data. However, a recent larger retrospective cohort reported a recurrence rate of 28.8% after long-term follow-up. Adjuvant therapies such as radiotherapy, triamcinolone, and 5-fluorouracil were frequently combined with dermal substitute reconstruction.

Conclusions: Dermal substitutes appear to be a promising adjunct in the surgical management of keloids, providing favorable aesthetic outcomes and low early recurrence rates. However, recurrence remains possible over long-term follow-up, and the independent effect of dermal matrices remains difficult to isolate due to frequent use of multimodal treatment protocols. Prospective studies with standardized surgical techniques and long-term follow-up are needed to better define the role of dermal substitutes in keloid surgery.

瘢痕疙瘩手术中的真皮替代品:116个病变的系统回顾和分析。
瘢痕疙瘩是一种病理性疤痕,其特点是纤维过度增生,手术切除后复发率高。真皮替代品被建议作为瘢痕疙瘩手术的辅助手段,因为它们可以恢复稳定的真皮基质,减少机械张力,并可能调节成纤维细胞的活性。然而,它们在预防复发方面的临床效果仍不明确。本研究旨在系统地回顾有关瘢痕疙瘩切除后使用皮肤替代品的现有文献。方法:根据PRISMA指南进行系统评价。检索了Medline, Embase, Web of Science从创立到2026年1月。符合条件的研究包括在瘢痕疙瘩完全切除后使用皮肤替代物的临床报告,至少有6个月的随访和明确的复发数据。病例报告、病例系列和会议摘要都包含了足够的临床细节。提取的变量包括患者特征、病变特征、替代类型、手术方案、辅助治疗、随访、复发。由于异质性,进行了描述性综合。结果:纳入20项研究,代表109例患者和116例瘢痕疙瘩病变。大多数出版物是病例系列或病例报告(IV-V级证据)。Integra®是最常用的替代品,其次是Pelnac®、AlloDerm®和Apligraf®。重建最常见的是采用两阶段的方法,延迟裂厚皮肤移植。6个月时,在提供早期随访数据的研究中,只有一例复发。然而,最近一项更大的回顾性队列报告长期随访后复发率为28.8%。辅助治疗如放疗、曲安奈德和5-氟尿嘧啶常与真皮替代物重建联合使用。结论:真皮替代物在瘢痕疙瘩的外科治疗中是一种很有前途的辅助手段,具有良好的美学效果和较低的早期复发率。然而,在长期随访中,复发仍然是可能的,并且由于频繁使用多模式治疗方案,皮肤基质的独立作用仍然难以分离。为了更好地确定真皮替代物在瘢痕疙瘩手术中的作用,需要标准化手术技术和长期随访的前瞻性研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
86
审稿时长
44 days
期刊介绍: Qu''elle soit réparatrice après un traumatisme, pratiquée à la suite d''une malformation ou motivée par la gêne psychologique dans la vie du patient, la chirurgie plastique et esthétique touche toutes les parties du corps humain et concerne une large communauté de chirurgiens spécialisés. Organe de la Société française de chirurgie plastique reconstructrice et esthétique, la revue publie 6 fois par an des éditoriaux, des mémoires originaux, des notes techniques, des faits cliniques, des actualités chirurgicales, des revues générales, des notes brèves, des lettres à la rédaction. Sont également présentés des analyses d''articles et d''ouvrages, des comptes rendus de colloques, des informations professionnelles et un agenda des manifestations de la spécialité.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书